Overview
Share price change
24h
Current
Min
1.23
Max
1.58
Income | -45M -67M |
|---|---|
Sales | -1.6M 33M |
EPS | -2.32 |
Profit margin | -200.476 |
Employees | 228 |
EBITDA | -44M -54M |
Next Earnings | 2 lis 2026 |
|---|
Market Cap | -3.8M 41M |
|---|---|
Previous open | 0.33 |
Previous close | 1.6 |
News Sentiment
By Acuity
50%
50%
146 / 339 Ranking in Healthcare
Karyopharm Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
10 wrz 2026, 20:07 UTC
Karyopharm Therapeutics is lower today, continuing a broader trend of weakness and remaining below its 20-day moving average. No specific news was identified.
Read
8 wrz 2026, 20:07 UTC
Karyopharm Therapeutics shares are lower after downgrades from Robert W. Baird and HC Wainwright, with a target price set at $3.00.
Read
2 wrz 2026, 20:08 UTC
Karyopharm Therapeutics Inc shares are lower today, having reached a session low earlier. The stock remains near the lower end of its one-month range.
Read
1 wrz 2026, 20:01 UTC
Karyopharm Therapeutics submitted a supplemental New Drug Application for XPOVIO, but shares are trading lower amid broader market concerns about rising oil prices and interest rates.
Read
31 sie 2026, 20:02 UTC
Karyopharm Therapeutics submitted a supplemental New Drug Application for XPOVIO, seeking Accelerated Approval for myelofibrosis treatment. Shares are gaining during Monday's session.
Read
28 sie 2026, 20:08 UTC
Karyopharm Therapeutics Inc shares declined during Friday's session amid rising U.S. Treasury yields, reflecting broader market trends. The stock finished near its one-month low.
Read
25 sie 2026, 20:07 UTC
Karyopharm Therapeutics Inc shares are higher during Tuesday's session, reaching a peak earlier in the day. The stock remains below its 20-day moving average.
Read
24 sie 2026, 19:16 UTC
Karyopharm Therapeutics Inc shares are lower today, reaching a session low amid ongoing market weakness and no specific news to explain the decline.
Read
21 sie 2026, 23:51 UTC
Karyopharm Therapeutics Inc shares are lower in after-market hours, following a brief uptick earlier. No specific news was identified to explain the decline.
Read
20 sie 2026, 20:02 UTC
Karyopharm Therapeutics is declining sharply amid a significant downturn in the Biotechnology sub-sector, nearing the lower end of its one-month trading range.
Read
18 sie 2026, 20:03 UTC
Karyopharm Therapeutics Inc is trading higher today, continuing its upward trend since Monday's close. The stock remains below its 20-day moving average.
Read
17 sie 2026, 23:46 UTC
Karyopharm Therapeutics shares are higher in after-market hours, following volatility earlier. Broader market pressures include geopolitical tensions and rising crude oil prices.
Read
14 sie 2026, 23:51 UTC
Karyopharm Therapeutics shares are higher in after-market trading, despite no specific news. Broader market sentiment reflects concerns from a decline in U.S. retail sales.
Read
13 sie 2026, 23:11 UTC
Karyopharm Therapeutics Inc shares are rising in after-market trading, showing a modest upward trend since Thursday's close despite recent significant declines.
Read
12 sie 2026, 19:56 UTC
Karyopharm Therapeutics Inc shares are lower today, retracing from an early high amid broader market conditions and geopolitical tensions. No specific news was identified.
Read
11 sie 2026, 20:01 UTC
Karyopharm Therapeutics Inc is trading higher today, having reached a peak earlier in the session. The stock remains below its 20-day moving average.
Read
10 sie 2026, 20:06 UTC
Karyopharm Therapeutics Inc shares are lower today, reversing an early gain and reaching a mid-morning low, with no specific news identified for the decline.
Read
7 sie 2026, 23:31 UTC
Karyopharm Therapeutics shares are lower in after-market hours, following a decline earlier despite gains in major tech stocks. No specific news was identified.
Read
6 sie 2026, 23:21 UTC
Karyopharm Therapeutics Inc shares are lower in after-market hours. The asset is trading below its 20-day moving average and near the lower end of its one-month range.
Read
5 sie 2026, 23:01 UTC
Karyopharm Therapeutics shares are lower in after-market hours, continuing a three-session decline amid broader market weakness from disappointing U.S. employment data.
Read
4 sie 2026, 23:46 UTC
Karyopharm Therapeutics shares are higher in after-market trading, though no specific news explains the movement. Broader market optimism may be influencing risk assets.
Read
3 sie 2026, 23:41 UTC
Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.
Read
1 sie 2026, 00:01 UTC
Karyopharm Therapeutics Inc shares are higher in after-market hours, reaching their highest cumulative return of the day despite recent underperformance.
Read
31 lip 2026, 23:31 UTC
Karyopharm Therapeutics shares rose during after-market hours, continuing a recovery from an earlier low. The stock remains below its 20-day moving average.
Read
30 lip 2026, 23:41 UTC
Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.
Read
29 lip 2026, 19:27 UTC
Karyopharm Therapeutics shares are lower as investor anxiety rises following the Federal Reserve's decision to maintain interest rates amid global uncertainties.
Read
27 lip 2026, 19:07 UTC
Karyopharm Therapeutics Inc shares are lower during Monday's trading session, reflecting ongoing weakness and broader market trends amid declining crude oil prices.
Read
24 lip 2026, 19:42 UTC
Karyopharm Therapeutics Inc. shares are higher during Friday's session, continuing a notable advance since Thursday, despite broader market challenges.
Read
23 lip 2026, 09:01 UTC
Karyopharm Therapeutics Inc shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite recent volatility and no specific news.
Read
22 lip 2026, 18:41 UTC
Karyopharm Therapeutics shares are declining amid market caution and rising crude oil prices. RBC Capital reaffirmed its Outperform rating with a $16 price target.
Read
Peer Comparison
Price change
Karyopharm Therapeutics Inc Forecast
Rating Consensus
By TipRanks
Moderate Buy
6 ratings
4
Buy
2
Hold
0
Sell
Based on 6 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.
Sentiment
By Acuity
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$